Participation of AT1 and Mas receptors in the modulation of inflammatory pain

Costa, Aline; Romero, Thiago Roberto Lima; Pacheco, Daniela F.; Perez, Andréa C.; Savernini, Átila; Santos, Robson A.S.; Duarte, Igor Dimitri Gama

doi:10.1016/j.peptides.2014.08.010

Cited by 14 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effects on macrophages and other leukocytes were probably also the reason for the higher susceptibility of Mas −/− mice in an endotoxic shock model [65,96]. Moreover, Mas −/− mice presented aggravated inflammatory pain [16] and allergic pulmonary inflammation [51].…”

Section: Mas Knockout Micementioning

confidence: 99%

Genetic Models

Alenina¹,

Bäder²

2019

Angiotensin-(1-7)

View full text Add to dashboard Cite

Section: Mas Knockout Micementioning

confidence: 99%

Genetic Models

Alenina¹,

Bäder²

2019

Angiotensin-(1-7)

View full text Add to dashboard Cite

“…Treatment with Ang(1–7) significantly attenuated bone pain suggesting it could be used in the relief of excruciating pain in advanced stage cancer patients (Forte et al, ). Intraplantar peripheral hyperalgesia induced by PGE 2 was reversed by a low‐dose of Ang(1–7) (Costa et al, ; Nemoto et al, ; Castor et al, ).…”

Section: The Progress In Coupling Ang(1–7) Functions With Mas1 Receptorsmentioning

confidence: 99%

Significance of angiotensin 1–7 coupling with MAS1 receptor and other GPCRs to the renin‐angiotensin system: IUPHAR Review 22

Karnik

Singh

Tirupula

et al. 2017

British J Pharmacology

View full text Add to dashboard Cite

This paper, written by members of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) subcommittees for the angiotensin receptors, confirms the existing nomenclature for these receptors and reviews our current understanding of their structure, pharmacology and functions, and their likely physiological roles in health and disease. More information on these receptor families can be found in the Concise Guide to PHARMACOLOGY Angiotensins are a group of hormonal peptides and include angiotensin II and angiotensin 1-7 produced by the renin angiotensin system. The biology, pharmacology and biochemistry of the receptors for angiotensins were extensively reviewed recently. In the review, the receptor nomenclature committee was not emphatic on designating MAS1 as the angiotensin 1-7 receptor on the basis of lack of classical G protein signalling and desensitization in response to angiotensin 1-7, as well as a lack of consensus on confirmatory ligand pharmacological analyses. A review of recent publications (2013-2016) on the rapidly progressing research on angiotensin 1-7 revealed that MAS1 and two additional receptors can function as 'angiotensin 1-7 receptors', and this deserves further consideration. In this review we have summarized the information on angiotensin 1-7 receptors and their crosstalk with classical angiotensin II receptors in the context of the functions of the renin angiotensin system. It was concluded that the receptors for angiotensin II and angiotensin 1-7 make up a sophisticated cross-regulated signalling network that modulates the endogenous protective and pathogenic facets of the renin angiotensin system.

show abstract

“…Indeed, we have noted that ketamine—a drug of abuse that binds to opioid receptors—may exert μ‐opioid effects that could account for the rapid antidepressant properties . Recent rodent studies indicate that the agent's analgesic properties are blocked by the μ‐opioid receptor antagonist naloxone ,. Thus, the strategy may carry greater risk in continued treatment than one might suspect .…”

Section: Alternative Mechanismsmentioning

confidence: 99%

“…22 Recent rodent studies indicate that the agent's analgesic properties are blocked by the -opioid receptor antagonist naloxone. 23,24 Thus, the strategy may carry greater risk in continued treatment than one might suspect. 25 In addition, the drug may exert its rapid effects through the second-messenger mammalian target of rapamycin system.…”

Section: Alternative Mechanismsmentioning

confidence: 99%

Issues encountered in recent attempts to develop novel antidepressant agents

Schatzberg

2015

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The development of new antidepressants has had mixed results over the past decade, with several notable failures. This paper reviews a number of major initiatives in the development of new antidepressant agents. Traditional strategies to build on agents that have monoaminergic effects at the synapse (e.g., vilazodone and ketamine) have been complemented with efforts that have emphasized devices and brain circuits (e.g., deep brain stimulation and transcranial magnetic stimulation) or chemical agents that modulate neuroendocrine systems (e.g., glucocorticoid antagonists, mixed melatonin agonists/serotonin type-2 receptor antagonists). Interestingly, chemical agents, such as onabotulinumtoxin A, may affect brain circuits as well. We present data from recent studies in drug and device development--reviewing progress made, stumbling blocks encountered, and issues that need to be addressed in future studies.

show abstract

Participation of AT1 and Mas receptors in the modulation of inflammatory pain

Cited by 14 publications

References 22 publications

Genetic Models

Genetic Models

Significance of angiotensin 1–7 coupling with MAS1 receptor and other GPCRs to the renin‐angiotensin system: IUPHAR Review 22

Issues encountered in recent attempts to develop novel antidepressant agents

Contact Info

Product

Resources

About